Atlas Trials

A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma

Clinical trial NCT06952478 · RECRUITING

Trial details

NCT number
NCT06952478
Sponsor
Celltrion
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Refractory or Relapsed Multiple Myeloma
Start date
2025-08-12
Primary completion
2027-11-15
Enrollment
486

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.